DGAP-News

Formycon appoints Dr. Stefan Glombitza as CEO and sets the course for the future by appointing the two experienced pharmaceutical managers Nicola Mikulcik and Dr. Andreas Seidl to the Executive Board

DGAP-News: Formycon AG / Key word(s): Personnel/Miscellaneous Formycon appoints Dr. Stefan Glombitza as CEO and sets the course for the future by appointing the two experienced pharmaceutical managers Nicola Mikulcik and Dr. Andreas Seidl to the Executive Board 19.05.2022 / 08:55 The issuer is solely responsible for the content of this announcement.

Press Release // May 19, 2022

Formycon appoints Dr. Stefan Glombitza as CEO and sets the course for the future by appointing the two experienced pharmaceutical managers Nicola Mikulcik and Dr. Andreas Seidl to the Executive Board

- Long-standing Chief Operating Officer (COO) Dr. Stefan Glombitza takes over the position of Chief Executive Officer (CEO)

- Previous CEO Dr. Carsten Brockmeyer leaves the Executive Board after 9 years with the regular end of contract and remains with the company as a scientific advisor

- Nicola Mikulcik and Dr. Andreas Seidl join the Executive Board as the Chief Business Officer (CBO) and Chief Scientific Officer (CSO)

- Enlargement and personnel alignment of the Executive Board ensures stable management of the company and sets the course for future commercial growth

Munich – Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) ("Formycon") today announced changes to its Executive Board, setting the stage for continued and stable leadership as the company moves towards becoming a global and fully integrated biosimilars pharmaceutical company.

Today and effective July 1, 2022, the Supervisory Board of Formycon appointed Dr. Stefan Glombitza, who has led Formycon's operational development activities as Chief Operating Officer (COO) since 2016, as Chief Executive Officer (CEO). Dr. Glombitza thus takes over the position from Dr. Carsten Brockmeyer, with whom he has worked closely in recent years to shape the strategic and organizational direction of the company.

The 57-year-old pharmacist, who holds a doctorate, can look back on more than 20 years of experience in internationally operating companies in the pharmaceutical industry and brings great expertise to this position from various global management and executive positions. In his role as CEO, he is to shape the strategic development of the company in the increasingly commercial phase and, together with his team of experts, implement the successful development of a continuously growing product portfolio.